45% reduction in the [11C]choline uptake (SUVmax) from 11.8 to 6.4 with a 78% decrease in PSA with a median of 4 months of bicalutamide therapy in patients with primary prostate cancer. This evidence concerns the gene KLK3 and Familial prostate cancer.